A detailed history of Signaturefd, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 329 shares of AXSM stock, worth $29,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
329
Previous 313 5.11%
Holding current value
$29,850
Previous $25,000 16.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$78.93 - $95.84 $1,262 - $1,533
16 Added 5.11%
329 $29,000
Q1 2024

May 03, 2024

BUY
$69.39 - $97.64 $16,653 - $23,433
240 Added 328.77%
313 $24,000
Q4 2023

Jan 31, 2024

SELL
$57.42 - $83.61 $3,674 - $5,351
-64 Reduced 46.72%
73 $5,000
Q3 2023

Nov 03, 2023

BUY
$69.25 - $82.21 $4,432 - $5,261
64 Added 87.67%
137 $9,000
Q2 2023

Aug 01, 2023

SELL
$58.41 - $90.35 $1,168 - $1,807
-20 Reduced 21.51%
73 $5,000
Q1 2023

Apr 28, 2023

SELL
$58.39 - $75.0 $37,019 - $47,550
-634 Reduced 87.21%
93 $5,000
Q4 2022

Jan 27, 2023

BUY
$39.94 - $79.72 $25,042 - $49,984
627 Added 627.0%
727 $56,000
Q2 2022

Aug 10, 2022

SELL
$21.74 - $46.75 $586 - $1,262
-27 Reduced 21.26%
100 $4,000
Q1 2022

May 02, 2022

SELL
$23.7 - $41.39 $10,688 - $18,666
-451 Reduced 78.03%
127 $5,000
Q4 2021

Jan 25, 2022

BUY
$30.7 - $43.36 $9,824 - $13,875
320 Added 124.03%
578 $22,000
Q3 2021

Oct 28, 2021

BUY
$19.91 - $68.26 $3,305 - $11,331
166 Added 180.43%
258 $9,000
Q2 2021

Jul 26, 2021

BUY
$50.63 - $73.5 $759 - $1,102
15 Added 19.48%
92 $6,000
Q1 2021

Apr 30, 2021

BUY
$55.91 - $81.44 $3,466 - $5,049
62 Added 413.33%
77 $4,000
Q4 2020

Feb 11, 2021

BUY
$66.31 - $86.52 $132 - $173
2 Added 15.38%
15 $1,000
Q3 2020

Nov 03, 2020

BUY
$68.34 - $85.84 $888 - $1,115
13 New
13 $1,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.89B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.